At 9.0% CAGR, the Europe Breast Cancer Therapeutics Market Is Projected to be Worth US$ 16,836.17 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Europe breast cancer therapeutics market was valued at US$ 8,446.96 million in 2022 and is expected to reach US$ 16,836.17 million by 2030, registering a CAGR of 9.0% from 2022 to 2030. Launch of several diagnostics and screening programs and growing burden of breast cancer are among the critical factors attributed to the Europe breast cancer therapeutics market expansion.

Advancements in personalized medicine, immunotherapy, combination therapies, drug delivery systems, liquid biopsies, AI, and patient-centric approaches are expected to shape the future of breast cancer treatment. These trends aim to improve treatment outcomes, reduce side effects, and enhance breast cancer patients overall quality of life.

Early disease detection plays a major role in improving patient outcomes and survival rates. Various organizations and healthcare providers are implementing screening programs to detect breast cancer at an initial stage when it is more treatable. The World Health Organization released a new Global Breast Cancer Initiative Framework in February 2013 that serves as a plan for fulfilling the goal of saving 2.5 million people from breast cancer by 2040. To achieve this, the new Framework, unveiled ahead of the World Cancer Day campaign, urges nations to follow the three pillars of health promotion for early detection, prompt diagnosis, and thorough management of breast cancer. These programs often include mammography, clinical breast exams, and self-breast exams to identify any abnormalities or signs of breast cancer. Implementing these programs has increased awareness and early detection of breast cancer cases, resulting in higher demand for effective therapeutics.

In addition, many advancements in diagnostic technologies have been witnessed across the globe. The National Library of Medicine states that early detection and precise diagnosis are essential for enhancing prognosis. Breast cancer assessment frequently makes use of radiographic imaging modalities such as digital mammography (DM), digital breast tomosynthesis (DBT), magnetic resonance imaging (MRI), ultrasound (US), and nuclear medicine procedures. Histopathology (HP) is the gold standard for determining the presence of cancer. Furthermore, using artificial intelligence (AI) technology to depict medical images quantitatively has significant potential for improving breast cancer segmentation, diagnosis, and prognosis. These technologies help healthcare providers identify the extent and characteristics of the tumor, allowing them to develop personalized treatment plans. Thus, the launch of diagnostic and screening programs, coupled with advancements in diagnostic technologies, contributes to the Europe breast cancer therapeutics market growth.

On the contrary, high cost of diagnosis and treatment hampers the growth Europe breast cancer therapeutics market.

Based on drug therapy, the Europe breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held 64.6% share of the Europe breast cancer therapeutics market in 2022, amassing US$ 5,452.90 million. It is projected to garner US$ 11,368.96 million by 2030 to expand at 9.6% CAGR during 2022-2030. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the Europe breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held 65.6% share of the Europe breast cancer therapeutics market in 2022, amassing US$ 5,541.26 million. It is projected to garner US$ 11,276.50 million by 2030 to expand at 9.3% CAGR during 2022-2030.

By distribution channel, the Europe breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held 68.8% share of Europe breast cancer therapeutics market in 2022, amassing US$ 5,809.90 million. It is projected to garner US$ 11,731.85 million by 2030 to expand at 9.2% CAGR during 2022-2030.

Based on country, the Europe breast cancer therapeutics market is categorized into Germany, France, UK, Italy, Spain, and the Rest of Europe. The UK held 25.3% share of Europe breast cancer therapeutics market in 2022, amassing US$ 2,139.25 million. It is projected to garner US$ 4,568.07 million by 2030 to expand at 9.9% CAGR during 2022-2030.

Key players operating in the Europe breast cancer therapeutics market are Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc, among others.

- In Jul 2021, Pfizer Inc. and Arvinas, Inc. entered into a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is in a Phase 2 dose expansion clinical trial for treating patients with ER+/HER2- locally advanced or metastatic breast cancer. Under the agreements terms, Pfizer paid Arvinas US$ 650 million upfront. Separately, Pfizer made a US$ 350 million equity investment in Arvinas. The companies will share worldwide development costs, commercialization expenses, and profits equally.

- In Mar 2023, Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with HR+/HER2- early breast cancer at risk of recurrence. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III early breast cancer regardless of nodal involvement.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com